NuVasive(R) to Participate in Investor Events in March 2013
SAN DIEGO, CA -- (Marketwire) -- 02/19/13 -- NuVasive, Inc. (NASDAQ:
NUVA), a medical device company focused on developing minimally
disruptive surgical products and procedures for the spine, announced
today that Quentin Blackford, Senior Vice President of Finance and
Treasury, is scheduled to present at the following investor events in
-- The Cowen 33rd Annual Health Care Conference at the Boston Marriot
Copley Place in Boston, Massachusetts, on Tuesday, March 5, 2013, at
10:00 a.m. EST.
-- Barclays Capital Global Healthcare Conference at the Loews Miami Hotel
in Miami, Florida, on Tuesday, March 12, 2013, at 9:00 a.m. EDT.
Alive webcast of both presentations will be available online from the
investor relations page of the Company's corporate website at
www.nuvasive.com. After the live webcasts, a replay of the
presentations will remain available on the website for 30 days.
NuVasive is a medical device company focused on developing minimally
disruptive surgical products and procedurally integrated solutions
for the spine. The Company is the 4th largest player in the $8.2
billion global spine market. NuVasive's principal product offering is
based on its Maximum Access Surgery, or MAS(R) platform. The MAS
platform combines several categories of solutions that collectively
minimize soft tissue disruption during spine surgery with maximum
visualization and safe, easy reproducibility for the surgeon: a
proprietary software-driven nerve avoidance system and
intra-operative monitoring support; MaXcess(R), a unique split-blade
retractor system; a wide variety of specialized implants; and several
biologic fusion enhancers. MAS significantly reduces surgery time and
returns patients to activities of daily living much faster than
conventional approaches. Having redefined spine surgery with the MAS
platform's lateral approach, known as eXtreme Lateral Interbody
Fusion, or XLIF(R), NuVasive has built an entire spine franchise.
With over 80 products today spanning lumbar, thoracic and cervical
applications, the Company will continue to expand and evolve its
offering predicated on its R&D focus and dedication to outstanding
vels supported by a culture of Absolute Responsiveness(R).
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties are described in NuVasive's press
releases and periodic filings with the Securities and Exchange
Commission. NuVasive's public filings with the Securities and
Exchange Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect events
or circumstances arising after the date on which it was made.
Michael J. Lambert
EVP & Chief Financial Officer
VP, Corporate Development & Investor Relations
Nicholas S. Laudico
The Ruth Group
Press spacebar to pause and continue. Press esc to stop.